Marea Therapeutics' monoclonal antibody MAR-001 demonstrated significant reductions in remnant cholesterol (up to 52.5%) and triglycerides (up to 52.7%) in Phase 2a cardiovascular disease trial.
Marea Therapeutics' MAR001 demonstrated clinically significant reductions in remnant cholesterol and triglycerides in a Phase 2a trial for cardiovascular disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.